4. Certara Inc. (NASDAQ:CERT)
Certara, Inc. (NASDAQ: CERT) reaches fourth place as one of the more financially established AI drug-development stocks. At approximately $7.94 per share and a market capitalization near $1.2 billion, it offers exposure to pharmaceutical research at a valuation below many healthcare software businesses.
The company provides biosimulation, predictive analytics and regulatory software used throughout the drug-development process. Its systems help researchers model how a medicine may behave inside the human body, select appropriate doses and design clinical trials more efficiently.
Biosimulation does not eliminate the need for laboratory experiments or human trials, but it can help researchers make better decisions before committing enormous amounts of capital. This is particularly important because bringing a single medicine to market can cost billions of dollars when failed programs and years of research are included.
Artificial intelligence can strengthen these capabilities by identifying patterns across clinical and biological information. Pharmaceutical customers may use the platform to narrow down potential treatments, improve trial designs and prepare regulatory submissions.
Second-quarter 2026 revenue reached $93.3 million. Software revenue grew 4% to $48.8 million, while services revenue declined 3% to $44.5 million. Total growth was only 1%, which explains part of the stock’s low valuation. Management nevertheless reaffirmed full-year revenue guidance, while its broader outlook called for an adjusted EBITDA margin of approximately 30% to 32%. The quarterly figures and guidance were provided through the official earnings release.
Slow growth is the main weakness, but the company has an established customer base and a business model that does not depend on one clinical trial. It can potentially benefit from rising pharmaceutical research activity regardless of which individual drug succeeds.
The shares may appeal to investors looking for an undervalued AI healthcare stock with stronger commercial foundations than most early-stage biotechnology names. It is unlikely to produce an overnight fortune, but improving software growth could lead to a meaningful valuation recovery.
